Results 231 to 240 of about 263,371 (305)

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul, Robert J. Mentz, Rebecca Young, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M. O'Connor, Kevin J. Anstrom, Paul W. Armstrong, for the VICTORIA Study Group   +13 more
wiley   +1 more source

The effectiveness and perceived value of feedback used in cardiac arrest simulation education: a mixed-method systematic review. [PDF]

Scand J Trauma Resusc Emerg Med
Vella R, Baker E, Akerjordet K, Thyer L.
europepmc   +1 more source

Design and simulation of a low-energy atomic silicon quantum-dot circuit with potential in internet of things applications. [PDF]

Sci Rep
Rasmi H, Mosleh M, Navimipour NJ, Ahmadpour SS, Kheyrandish M.   +4 more
europepmc   +1 more source

CGM-derived efficacy and overall safety of once-weekly insulin efsitora alfa (efsitora) relative to day of administration in adults with type 2 diabetes. [PDF]

Diabetes Obes Metab
Martens T, Battelino T, Heller S, Bhargava A, Ji L, Murthy S, Threlkeld RJ, Li X, Murro AL, Syring K, Patel V.   +10 more
europepmc   +1 more source

The Impact of Low EHR-Continuity on Effect Estimates: Evidence from Two EHR-Medicare Linked Databases. [PDF]

Clin Epidemiol
Jin Y, Tong AY, Wyss R, Yang J, Lin KJ.
europepmc   +1 more source

Background HIV Incidence in PURPOSE 1 and 2 PrEP Trials. [PDF]

Clin Infect Dis
Parienti JJ.
europepmc   +1 more source